Ultrasensitive p24 antigen assay for diagnosis of perinatal human immunodeficiency virus type 1 infection.

We evaluated an ultrasensitive p24 antigen enzyme immunosorbent assay on 802 plasma specimens from 582 infants and children of 0 to 180 days of age. Overall sensitivity and specificity were 91.7% and 98.

Evaluation of an ultrasensitive p24 antigen assay as a potential alternative to human immunodeficiency virus type 1 RNA viral load assay in resource-limited settings.

An inexpensive enzyme-linked immunosorbent assay method for human immunodeficiency virus type 1 quantitation, ultrasensitive p24 antigen assay (Up24), was compared with RNA viral load assay (VL). Up24 had 100% sensitivity of detection at a viral load of >/=30,000, with sensitivity of 46.4% at a viral load of <30,000 (232 specimens from 65 seropositive subjects).

Antiretroviral drug resistance in human immunodeficiency virus-infected source patients for occupational exposures to healthcare workers.

Objective: To assess the prevalence of HIV antiretroviral resistance among source patients for occupational HIV exposures.

Design: Blood and data (eg, stage of HIV, previous antiretroviral drug therapy, and HIV RNA viral load) were collected from HIV-infected patients who were source patients for occupational exposures.

Setting: Seven tertiary-care medical centers in five U.